Charting Brain Asymmetry Across the Human Lifespan

A peer-reviewed study validated Centile Bioscience's population-referenced measurement approach for detecting neurodegeneration at the level of an individual patient, distinguishing Alzheimer's disease from matched controls and extending to frontotemporal dementia. The result adds independent, peer-reviewed evidence that Centile Bio's method produces meaningful endpoints for clinical research and drug development.

Josh Bernstock, MD, PhD, MPH, a neurosurgeon-scientist and entrepreneur affiliated with Texas Children’s Hospital, Baylor College of Medicine, and MD Anderson, is one of Centile Bioscience's co-founders. As Chief Medical Officer, he guides the company's clinical direction, ensuring its technology delivers practical value in clinical care, drug development, and research.

Hannah Mamuszka, a health-economics leader and diagnostics expert, joined Centile Bioscience's Advisory Board, where she guides the company's market-access, reimbursement, and health-economics strategy as Centile's platform moves toward clinical and commercial use.